

Circular No.: (11) 2026

To: All Invoicing Companies (MAHs, Manufacturers, Exporting Distributors), All Agents/Distributors (Importers), and All Dispensers (Hospitals, Pharmacies, Clinics) in the Kingdom of Bahrain.

Subject: Transition to the TATABU Pharmaceutical Traceability System

Further to NHRA Circular No. (16) 2025 regarding the preparation for the transition to a new pharmaceutical traceability platform, the National Health Regulatory Authority (NHRA) hereby informs all stakeholders that Antares Vision S.p.A. has been selected by NHRA to operate the new national pharmaceutical traceability platform under the name

“TATABU Pharmaceutical Traceability System”

The registration portal and the associated pharmaceutical traceability platform are operated by Antares Vision S.p.A., acting as the technical service provider appointed by NHRA to support the implementation and operation of the TATABU Pharmaceutical Traceability System and the Kingdom of Bahrain’s Pharmaceutical Traceability Programme.

NHRA is currently coordinating the transition activities to ensure a seamless and uninterrupted migration from the existing system to the TATABU Pharmaceutical Traceability System, while maintaining continuity of regulatory operations and pharmaceutical supply chain activities within the Kingdom of Bahrain.

The Authority recognizes the importance of ensuring uninterrupted pharmaceutical availability and will therefore continue to support stakeholders throughout the transition and onboarding phases.

Manufacturers, Invoicing Companies, Wholesalers and other relevant stakeholders will receive further information in subsequent communications regarding:

- onboarding procedures
- technical integration requirements
- transition timelines

مكتب الرئيس التنفيذي

Chief Executive Office

- training and implementation activities
- registration and access to the new platform

The current transition phase is focused primarily on Manufacturers, Invoicing Companies and Wholesalers that represent the primary entry point of pharmaceutical products into the Bahraini market.

Until further notice, all stakeholders are required to continue complying with their existing reporting and operational obligations through the currently active traceability system.

Additional information and implementation guidance will be communicated by NHRA through subsequent circulars and direct stakeholder communications.

Support

For inquiries or technical assistance, stakeholders are requested to contact:

pharma-support@nhra.bh



Dr. Ahmed Mohammed Al Ansari
Chief Executive Officer

